Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03844945
Recruitment Status : Completed
First Posted : February 19, 2019
Last Update Posted : November 15, 2019
Sponsor:
Information provided by (Responsible Party):
Aerie Pharmaceuticals

Brief Summary:
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan

Condition or disease Intervention/treatment Phase
Open Angle Glaucoma Ocular Hypertension Drug: Netarsudil Ophthalmic Solution 0.01% Drug: Netarsudil Ophthalmic Solution 0.02% Drug: Netarsudil Ophthalmic Solution 0.04% Other: Netarsudil Ophthalmic Solution Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 215 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety, Ocular Hypotensive Efficacy and Optimum Dose Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Actual Study Start Date : March 19, 2019
Actual Primary Completion Date : September 19, 2019
Actual Study Completion Date : September 19, 2019


Arm Intervention/treatment
Experimental: Netarsudil Ophthalmic Solution 0.01%
1 drop daily into each eye in the evening for 28 days
Drug: Netarsudil Ophthalmic Solution 0.01%
Topical sterile ophthalmic solution

Experimental: Netarsudil Ophthalmic Solution 0.02%
1 drop daily into each eye in the evening for 28 days
Drug: Netarsudil Ophthalmic Solution 0.02%
Topical sterile ophthalmic solution
Other Name: Rhopressa®

Experimental: Netarsudil Ophthalmic Solution 0.04%
1 drop daily into each eye in the evening for 28 days
Drug: Netarsudil Ophthalmic Solution 0.04%
Topical sterile ophthalmic solution

Placebo Comparator: Netarsudil Ophthalmic Solution Placebo
1 drop daily into each eye in the evening for 28 days
Other: Netarsudil Ophthalmic Solution Placebo
Topical sterile ophthalmic solution




Primary Outcome Measures :
  1. Intraocular Pressure (IOP) [ Time Frame: 29 Days ]
    Mean diurnal IOP within a treatment by Goldman Applanation Tonometry



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Must be 20 years of age or older
  2. Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) in both eyes. (OAG in one eye and OHT in the fellow eye is acceptable)
  3. BCVA 0.1 or better in decimal unit using Landolt-C chart or its equivalent
  4. Able and willing to give signed informed consent and following study instructions

Exclusion Criteria:

  1. Clinically significant ocular diseases
  2. Pseudoexfoliation or pigment dispersion component glaucoma, history of narrow angle closure glaucoma or narrow angles
  3. Previous glaucoma intraocular surgery
  4. Refractive surgery in either eye
  5. Ocular trauma
  6. Ocular infection or inflammation
  7. Known hypersensitivity to benzalkonium chloride or excipient of netarsudil ophthalmic solution
  8. Cannot demonstrate proper delivery of the eye drop
  9. Clinically significant abnormalities in screen lab tests
  10. Clinically significant systemic disease
  11. Participation in any investigational study within 30 days of screening
  12. Women of child-bearing potential who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03844945


Locations
Show Show 25 study locations
Sponsors and Collaborators
Aerie Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Theresa Heah, MD, MBA Aerie Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Aerie Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03844945    
Other Study ID Numbers: AR-13324-CS208
First Posted: February 19, 2019    Key Record Dates
Last Update Posted: November 15, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Aerie Pharmaceuticals:
Glaucoma
Ocular Hypertension
Open-Angle Glaucoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions